Hansa Biopharma AB (ST:HNSA) — Market Cap & Net Worth
Market Cap & Net Worth: Hansa Biopharma AB (HNSA)
Hansa Biopharma AB (ST:HNSA) has a market capitalization of $393.01 Million (Skr3.65 Billion) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #13626 globally and #217 in its home market, demonstrating a -12.73% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hansa Biopharma AB's stock price Skr36.62 by its total outstanding shares 99725931 (99.73 Million). Also see balance sheet size of Hansa Biopharma AB for a full breakdown of the balance sheet.
Hansa Biopharma AB Market Cap History: 2015 to 2026
Hansa Biopharma AB's market capitalization history from 2015 to 2026. Data shows growth from $271.52 Million to $393.01 Million (1.69% CAGR). Also see cash flow conversion of Hansa Biopharma AB for how efficiently the company converts equity into cash flow.
Hansa Biopharma AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hansa Biopharma AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check HNSA live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.46x
Hansa Biopharma AB's market cap is 2.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $271.52 Million | $5.43 Million | -$66.27 Million | 49.97x | N/A |
| 2016 | $1.25 Billion | $2.58 Million | -$111.13 Million | 484.80x | N/A |
| 2017 | $2.68 Billion | $3.44 Million | -$176.66 Million | 777.94x | N/A |
| 2018 | $2.97 Billion | $3.36 Million | -$247.97 Million | 884.65x | N/A |
| 2019 | $899.89 Million | $3.36 Million | -$360.01 Million | 267.51x | N/A |
| 2020 | $2.58 Billion | $6.10 Million | -$420.85 Million | 423.09x | N/A |
| 2021 | $953.01 Million | $33.88 Million | -$548.28 Million | 28.13x | N/A |
| 2022 | $528.23 Million | $154.53 Million | -$611.13 Million | 3.42x | N/A |
| 2023 | $281.18 Million | $134.09 Million | -$831.72 Million | 2.10x | N/A |
| 2024 | $420.70 Million | $171.32 Million | -$807.24 Million | 2.46x | N/A |
Competitor Companies of HNSA by Market Capitalization
Companies near Hansa Biopharma AB in the global market cap rankings as of September 19, 2026. Review Hansa Biopharma AB tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Hansa Biopharma AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Hansa Biopharma AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Hansa Biopharma AB's market cap moved from $271.52 Million to $ 393.01 Million, with a yearly change of 1.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr393.01 Million | +6.58% |
| 2025 | Skr368.76 Million | -12.35% |
| 2024 | Skr420.70 Million | +49.62% |
| 2023 | Skr281.18 Million | -46.77% |
| 2022 | Skr528.23 Million | -44.57% |
| 2021 | Skr953.01 Million | -63.06% |
| 2020 | Skr2.58 Billion | +186.70% |
| 2019 | Skr899.89 Million | -69.71% |
| 2018 | Skr2.97 Billion | +10.94% |
| 2017 | Skr2.68 Billion | +114.16% |
| 2016 | Skr1.25 Billion | +360.47% |
| 2015 | Skr271.52 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Hansa Biopharma AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $393.01 Million USD |
| MoneyControl | $393.01 Million USD |
| MarketWatch | $393.01 Million USD |
| marketcap.company | $393.01 Million USD |
| Reuters | $393.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant pa… Read more